UZH-Logo

Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury


Kaiser, P R; Valko, P O; Werth, E; Thomann, J; Meier, J; Stocker, R; Bassetti, C L; Baumann, C R (2010). Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury. Neurology, 75(20):1780-1785.

Abstract

BACKGROUND: Excessive daytime sleepiness (EDS) and fatigue are common symptoms after traumatic brain injury (TBI), but there is no specific treatment for affected patients. With this pilot study, we aimed at studying the effect of daily modafinil on posttraumatic EDS and fatigue.

METHODS: We conducted a prospective, double-blind, randomized, placebo-controlled pilot study in 20 patients with TBI who had fatigue or EDS or both. After baseline examinations (questionnaires including the Epworth Sleepiness Scale to assess EDS and the Fatigue Severity Scale to assess fatigue, actigraphy, polysomnography, maintenance of wakefulness test, and psychomotor vigilance test), 10 patients received 100 to 200 mg modafinil every morning, and 10 patients were treated with placebo. After a 6-week treatment period, all examinations were repeated.

RESULTS: EDS improved significantly in patients with TBI who were treated with modafinil, compared with the placebo group. Similarly, the ability to stay awake on the maintenance of wakefulness test improved only in the modafinil group. Modafinil, however, had no impact on posttraumatic fatigue. Clinically relevant side effects were not observed.

CONCLUSION: This study indicates that modafinil is effective and well tolerated in the treatment of posttraumatic EDS but not of fatigue. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that modafinil (100-200 mg daily) improves posttraumatic EDS compared with placebo. This study provides Class I evidence that modafinil (100-200 mg daily) does not improve posttraumatic fatigue compared with placebo.

BACKGROUND: Excessive daytime sleepiness (EDS) and fatigue are common symptoms after traumatic brain injury (TBI), but there is no specific treatment for affected patients. With this pilot study, we aimed at studying the effect of daily modafinil on posttraumatic EDS and fatigue.

METHODS: We conducted a prospective, double-blind, randomized, placebo-controlled pilot study in 20 patients with TBI who had fatigue or EDS or both. After baseline examinations (questionnaires including the Epworth Sleepiness Scale to assess EDS and the Fatigue Severity Scale to assess fatigue, actigraphy, polysomnography, maintenance of wakefulness test, and psychomotor vigilance test), 10 patients received 100 to 200 mg modafinil every morning, and 10 patients were treated with placebo. After a 6-week treatment period, all examinations were repeated.

RESULTS: EDS improved significantly in patients with TBI who were treated with modafinil, compared with the placebo group. Similarly, the ability to stay awake on the maintenance of wakefulness test improved only in the modafinil group. Modafinil, however, had no impact on posttraumatic fatigue. Clinically relevant side effects were not observed.

CONCLUSION: This study indicates that modafinil is effective and well tolerated in the treatment of posttraumatic EDS but not of fatigue. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that modafinil (100-200 mg daily) improves posttraumatic EDS compared with placebo. This study provides Class I evidence that modafinil (100-200 mg daily) does not improve posttraumatic fatigue compared with placebo.

Citations

45 citations in Web of Science®
51 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

3 downloads since deposited on 26 Jan 2011
2 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2010
Deposited On:26 Jan 2011 18:04
Last Modified:05 Apr 2016 14:39
Publisher:American Academy of Neurology
ISSN:0028-3878
Additional Information:Comment in: Neurology. 2010 Nov 16;75(20):1764-5.
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:10.1212/WNL.0b013e3181fd62a2
PubMed ID:21079179
Permanent URL: http://doi.org/10.5167/uzh-43366

Download

[img]
Preview
Content: Published Version
Filetype: PDF
Size: 365kB
View at publisher

TrendTerms

TrendTerms displays relevant terms of the abstract of this publication and related documents on a map. The terms and their relations were extracted from ZORA using word statistics. Their timelines are taken from ZORA as well. The bubble size of a term is proportional to the number of documents where the term occurs. Red, orange, yellow and green colors are used for terms that occur in the current document; red indicates high interlinkedness of a term with other terms, orange, yellow and green decreasing interlinkedness. Blue is used for terms that have a relation with the terms in this document, but occur in other documents.
You can navigate and zoom the map. Mouse-hovering a term displays its timeline, clicking it yields the associated documents.

Author Collaborations